Ironwood Pharmaceuticals Inc represents a strong dedication to improving the lives of patients through innovative medicines. Their corporate philosophy is centered around delivering breakthrough treatments and therapies that address unmet medical needs. With a focus on gastrointestinal diseases such as irritable bowel syndrome with constipation (IBS-C) and gastrointestinal (GI) disorders, Ironwood Pharmaceuticals aims to provide effective solutions for patients worldwide. Their commitment to scientific excellence, collaboration, and patient advocacy drives their pursuit of transformative healthcare solutions. Ironwood Pharmaceuticals Inc is committed to making a positive impact within the pharmaceutical industry by advancing patient care and wellbeing.

Ironwood Pharmaceuticals Inc is primarily present in the United States.

Ironwood Pharmaceuticals Inc has achieved significant milestones since its inception. Notably, the company successfully developed and gained regulatory approval for its flagship drug, LINZESS® (linaclotide), which is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc also formed a strategic collaboration with Allergan plc (now part of AbbVie Inc) to co-develop and co-commercialize LINZESS®. Moreover, the company advanced its pipeline with the development of potential treatments for various gastrointestinal and renal disorders. Ironwood Pharmaceuticals Inc's commitment to innovation and its focus on improving patients' lives solidify its position as a leading pharmaceutical company in the market.

Ironwood Pharmaceuticals Inc is a leading biotechnology company specializing in the development and commercialization of innovative medicines. Founded in 1998, Ironwood has since focused on advancing treatments for gastrointestinal diseases and fibrotic conditions. With a strong dedication to research and development, the company has successfully brought several approved drugs to market. Ironwood Pharmaceuticals Inc has established itself as a key player in the pharmaceutical industry, continuously striving to improve patients' lives. Through its commitment to scientific excellence and breakthrough therapies, Ironwood Pharmaceuticals Inc has positioned itself as a trusted name in the healthcare sector.

The main competitors of Ironwood Pharmaceuticals Inc in the market include Allergan plc, AstraZeneca plc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.

Ironwood Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Ironwood Pharmaceuticals Inc revolves around developing and commercializing innovative medicines for patients with gastrointestinal (GI) diseases. The company focuses on discovering, developing, and marketing medicines for indications like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc leverages its expertise in the GI field to identify and advance potential therapies that address significant unmet needs in patient care. By prioritizing research and development, the company aims to improve the lives of individuals suffering from GI disorders and enhance their overall quality of life.

Το Ironwood Pharmaceuticals P/E είναι 11,93.

Το KUV της εταιρείας Ironwood Pharmaceuticals είναι 2,31.

Το AlleAktien Qualitätsscore για το Ironwood Pharmaceuticals είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Ironwood Pharmaceuticals είναι 418,25 Εκ. USD.

Το αναμενόμενη Ironwood Pharmaceuticals κέρδος είναι 81,07 Εκ. USD.

Ironwood Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the research, development, and commercialization of innovative drugs for the treatment of serious diseases. The business model of Ironwood is based on the invention and commercialization of new drugs to improve the health and quality of life of patients. The company specializes in the development of therapeutics in the fields of gastroenterology, hepatology, oncology, and neuroscience. An important segment of Ironwood's business model is partnerships with other companies. Ironwood collaborates with numerous partners and hospitals to optimize the research and development of therapeutics. For example, Ironwood works with the Canadian company Allergan to market the gastrointestinal motility agent Linzess. Ironwood also has its own sales and marketing organization that focuses on promoting and marketing its products. The company aims to bring its products to the global market and maintain its leading position in the industry. One of Ironwood's leading products is Linzess, the first and only prescription medication for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. Linzess aims to alleviate the symptoms of these conditions by increasing intestinal motility and facilitating bowel movements. Another important product of Ironwood is Zurampic, a medication for the treatment of gout in adults in combination with a xanthine oxidase inhibitor. Zurampic helps reduce uric acid in the body by increasing its excretion through the kidneys. Ironwood also has products in the pipeline that are in different stages of clinical development. These include IW-3718 for the treatment of reflux diseases and Olinciguat for the treatment of cystic fibrosis-associated respiratory complications. Overall, Ironwood has successfully built a business model specializing in the discovery and development of new drugs, with a focus on gastroenterology, hepatology, oncology, and neuroscience. The company works closely with partners and hospitals to optimize the research and development of therapeutics and market its products worldwide. With leading products like Linzess and Zurampic, along with promising products in the pipeline, Ironwood remains an important player in the industry.

Η Ironwood Pharmaceuticals καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Ironwood Pharmaceuticals αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Ironwood Pharmaceuticals είναι US46333X1081.

Το WKN της Ironwood Pharmaceuticals είναι A0X789.

Ο τίκερ της Ironwood Pharmaceuticals είναι IRWD.

Κατά τους τελευταίους 12 μήνες η Ironwood Pharmaceuticals κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Ironwood Pharmaceuticals προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Ironwood Pharmaceuticals ανέρχεται σήμερα στο .

Ironwood Pharmaceuticals πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Ironwood Pharmaceuticals πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Ironwood Pharmaceuticals ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Ironwood Pharmaceuticals από την 5/7/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 5/7/2024.

Η τελευταία μερίσματος έγινε στις 5/7/2024.

Το έτος 2023, η Ironwood Pharmaceuticals διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Ironwood Pharmaceuticals καταβάλλονται σε USD.